

1

2

3 **Varicose veins in the legs: the diagnosis**
4 **and management of varicose veins**

5

6

7

NICE guideline

8

Draft for consultation, February 2013

9

If you wish to comment on this version of the guideline, please be aware that all the supporting information and evidence is contained in the full version.

10

11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Contents

Introduction	3
Strength of recommendations	5
Terms used in this guideline	7
Key priorities for implementation	7
1 Recommendations	9
1.1 Information for people with varicose veins	9
1.2 Referral to a vascular service	10
1.3 Assessment and treatment in a vascular service	10
1.4 Management during pregnancy	11
2 Research recommendations	11
3 Other information	15
3.1 Scope and how this guideline was developed	15
3.2 Related NICE guidance	16
4 The Guideline Development Group, National Collaborating Centre and NICE project team.....	17

1 **Introduction**

2 Varicose veins are dilated, often palpable, subcutaneous veins with reversed
3 blood flow. They are most commonly found in the legs. Estimates of the
4 prevalence of varicose veins vary. Visible varicose veins in the lower limbs are
5 estimated to affect at least a third of the population. Risk factors for
6 developing varicose veins are unclear, although prevalence rises with age and
7 they often develop during pregnancy. In some people, varicose veins are
8 asymptomatic or cause only mild symptoms, but in others, they cause pain,
9 aching or itching and can have a significant effect on their quality of life.

10 Varicose veins may become more severe over time and can lead to
11 complications such as changes in skin pigmentation, bleeding or venous
12 ulceration. It is not known which people will develop more severe disease but
13 it is estimated that 3–6% of people who have varicose veins in their lifetime
14 will develop venous ulcers.

15 There are several options for the management of varicose veins, including:

- 16 • advice and reassurance
17 • compression hosiery
18 • interventional treatments (endothermal ablation, foam sclerotherapy and
19 surgery).

20 In 2009/10, there were 35,659 varicose veins procedures carried out in the
21 NHS. These interventions increase workload and costs substantially. There is
22 no definitive system for identifying which patients will benefit the most from
23 interventional treatment and no established framework within the NHS for the
24 diagnosis and management of varicose veins. This has resulted in wide
25 regional variations in the management of varicose veins in the UK.

26 The guideline will assume that prescribers will use a drug's summary of
27 product characteristics to inform decisions made with individual patients.

28

1 **Patient-centred care**

2 This guideline offers best practice advice on the care of adults aged 18 years
3 and over with varicose veins in the legs.

4 Patients and healthcare professionals have rights and responsibilities as set
5 out in the [NHS Constitution for England](#) – all NICE guidance is written to
6 reflect these. Treatment and care should take into account individual needs
7 and preferences. Patients should have the opportunity to make informed
8 decisions about their care and treatment, in partnership with their healthcare
9 professionals. If someone does not have the capacity to make decisions,
10 healthcare professionals should follow the [Department of Health's advice on
11 consent](#), the [code of practice that accompanies the Mental Capacity Act](#) and
12 the supplementary [code of practice on deprivation of liberty safeguards](#). In
13 Wales, healthcare professionals should follow [advice on consent from the
14 Welsh Government](#).

15 NICE has produced guidance on the components of good patient experience
16 in adult NHS services. All healthcare professionals should follow the
17 recommendations in [Patient experience in adult NHS services](#).

18

1 **Strength of recommendations**

2 Some recommendations can be made with more certainty than others. The
3 Guideline Development Group makes a recommendation based on the trade-
4 off between the benefits and harms of an intervention, taking into account the
5 quality of the underpinning evidence. For some interventions, the Guideline
6 Development Group is confident that, given the information it has looked at,
7 most patients would choose the intervention. The wording used in the
8 recommendations in this guideline denotes the certainty with which the
9 recommendation is made (the strength of the recommendation).

10 For all recommendations, NICE expects that there is discussion with the
11 patient about the risks and benefits of the interventions, and their values and
12 preferences. This discussion aims to help them to reach a fully informed
13 decision (see also 'Patient-centred care').

14 ***Interventions that must (or must not) be used***

15 We usually use 'must' or 'must not' only if there is a legal duty to apply the
16 recommendation. Occasionally we use 'must' (or 'must not') if the
17 consequences of not following the recommendation could be extremely
18 serious or potentially life threatening.

19 ***Interventions that should (or should not) be used – a 'strong'*** 20 ***recommendation***

21 We use 'offer' (and similar words such as 'refer' or 'advise') when we are
22 confident that, for the vast majority of patients, an intervention will do more
23 good than harm, and be cost effective. We use similar forms of words (for
24 example, 'Do not offer...') when we are confident that an intervention will not
25 be of benefit for most patients.

26 ***Interventions that could be used***

27 We use 'consider' when we are confident that an intervention will do more
28 good than harm for most patients, and be cost effective, but other options may
29 be similarly cost effective. The choice of intervention, and whether or not to
30 have the intervention at all, is more likely to depend on the patient's values
Varicose veins in the legs: NICE guideline DRAFT (February 2013)

DRAFT FOR CONSULTATION

1 and preferences than for a strong recommendation, and so the healthcare
2 professional should spend more time considering and discussing the options
3 with the patient.

4

5

1 **Terms used in this guideline**

2 **Symptomatic varicose veins** Veins found in association with troublesome
3 lower-limb symptoms (typically pain, aching, discomfort, swelling, heaviness,
4 and itching) that are thought to be caused by superficial venous reflux and for
5 which no other more likely cause is apparent

6 **Vascular service** A team of healthcare professionals who have the skills to
7 undertake a full clinical and duplex ultrasound assessment and provide a full
8 range of treatment

9 **Key priorities for implementation**

10 The following recommendations have been identified as priorities for
11 implementation.

12 **Referral to a vascular service**

- 13 • Refer people to a vascular service if they have:
 - 14 – symptomatic primary or recurrent varicose veins **or**
 - 15 – lower-limb skin changes (such as pigmentation or eczema)
 - 16 – thought to be caused by chronic venous insufficiency.

- 17 • Refer people to a vascular service if they have:
 - 18 – a venous leg ulcer (a break in the skin below the knee that
 - 19 – has not healed within 2 weeks) **or**
 - 20 – a healed venous leg ulcer.

21 **Assessment and treatment in a vascular service**

- 22 • Consider using duplex ultrasound to confirm the diagnosis and plan
23 treatment for people with suspected primary or recurrent varicose veins.
- 24 • Offer interventional treatment to people with confirmed varicose veins and
25 truncal reflux as follows:
 - 26 – Offer endothermal ablation.

- 1 – If endothermal ablation is not suitable or is declined, offer
2 ultrasound-guided foam sclerotherapy¹.
3 – If ultrasound-guided foam sclerotherapy is unsuitable or is
4 declined, offer surgery.

5 If incompetent varicose tributaries are to be treated, consider
6 treating them at the same time.

- 7 • Offer compression hosiery only if interventional treatment is not suitable or
8 is declined.

9

10

¹Recommendation linked to [Ultrasound-guided foam sclerotherapy for varicose veins](#) (IPG440).

1 **1 Recommendations**

2 The following guidance is based on the best available evidence. The [full](#)
3 [guideline](#) [\[hyperlink to be added for final publication\]](#) gives details of the
4 methods and the evidence used to develop the guidance.

5 All recommendations relate to adults aged 18 years and over.

6 **1.1 Information for people with varicose veins**

7 1.1.1 Give people who present with varicose veins information that
8 includes:

- 9 • an explanation of what varicose veins are
- 10 • possible causes of varicose veins
- 11 • the likelihood of progression and possible complications,
12 including deep vein thrombosis, skin changes, leg ulcers,
13 bleeding and thrombophlebitis. Address any misconceptions the
14 person may have about the risks of developing complications
- 15 • treatment options, including symptom relief, compression and a
16 brief overview of interventional treatments
- 17 • lifestyle changes that may help, for example:
 - 18 – weight loss (for guidance on weight management, see
19 [Obesity](#) [NICE clinical guideline 43])
 - 20 – light to moderate physical activity (for example, walking or
21 swimming)
 - 22 – avoiding factors that are known to make their symptoms
23 worse if possible (for example, some people find prolonged
24 standing or hot baths make their symptoms worse)
- 25 • when and where to seek further medical help.

26 1.1.2 When discussing treatment for varicose veins at the vascular
27 service, tell the person:

- 28 • what treatment options are available
- 29 • the expected outcomes and possible adverse events of each
30 treatment option

- 1 • that new varicose veins may develop after treatment
- 2 • that they may need more than 1 session of treatment
- 3 • that the chance of recurrence after treatment for recurrent
- 4 varicose veins is higher than for primary varicose veins.

5 **1.2 Referral to a vascular service**

6 1.2.1 Refer people with bleeding varicose veins to be seen by a
7 vascular service immediately or within 24 hours.

8 1.2.2 Refer people with a recent history of minor bleeding from varicose
9 veins to be seen by a vascular service within 2 weeks.

10 1.2.3 Refer people to a vascular service if they have:

- 11 • symptomatic primary or recurrent varicose veins **or**
- 12 • lower-limb skin changes (such as pigmentation or eczema)
- 13 thought to be caused by chronic venous insufficiency.

14 1.2.4 Refer people with superficial vein thrombosis (characterised by the
15 appearance of hard, painful veins) and suspected superficial
16 venous incompetence to a vascular service.

17 1.2.5 Refer people to a vascular service if they have:

- 18 • a venous leg ulcer (a break in the skin below the knee that has
- 19 not healed within 2 weeks) **or**
- 20 • a healed venous leg ulcer.

21 **1.3 Assessment and treatment in a vascular service**

22 1.3.1 Consider using duplex ultrasound to confirm the diagnosis and to
23 plan treatment for people with suspected primary or recurrent
24 varicose veins.

25 1.3.2 Offer interventional treatment to people with confirmed varicose
26 veins and truncal reflux as follows:

- 27 • Offer endothermal ablation.

- 1 • If endothermal ablation is not suitable or is declined, offer
2 ultrasound-guided foam sclerotherapy².
3 • If ultrasound-guided foam sclerotherapy is unsuitable or is
4 declined, offer surgery.

5 If incompetent varicose tributaries are to be treated, consider
6 treating them at the same time.

7 1.3.3 Offer compression hosiery only if interventional treatment is not
8 suitable or is declined.

9 1.3.4 Do not offer compression bandaging or hosiery for more than
10 7 days after completion of interventional treatment for varicose
11 veins.

12 **1.4 Management during pregnancy**

13 1.4.1 Give pregnant women presenting with varicose veins information
14 on the effect of pregnancy on varicose veins.

15 1.4.2 Do not carry out interventional treatment for varicose veins during
16 pregnancy other than in exceptional circumstances.

17 1.4.3 Consider compression hosiery for symptom relief of leg swelling
18 associated with varicose veins during pregnancy.

19 **2 Research recommendations**

20 The Guideline Development Group has made the following recommendations
21 for research, based on its review of evidence, to improve NICE guidance and
22 patient care in the future. The Guideline Development Group's full set of
23 research recommendations is detailed in appendix N of the [full guideline](#)
24 [\[hyperlink to be added for final publication\]](#)

² Recommendation linked to [Ultrasound-guided foam sclerotherapy for varicose veins](#) (IPG440).
Varicose veins in the legs: NICE guideline DRAFT (February 2013)

1 **2.1** ***Natural history of varicose veins***

2 In people with varicose veins at CEAP (Clinical, etiological, anatomical and
3 pathophysiological) stage C2 or C3, what are the factors that influence
4 progression of the disease to CEAP stages C5 or C6?

5 **Why this is important**

6 The evidence review for the guideline showed a lack of high-quality evidence
7 on the progression of varicose veins from CEAP stage C2 or C3 to more
8 serious varicose veins disease. A large observational prospective cohort
9 study, similar to the Framingham or BONN veins studies, should be
10 undertaken. The study should recruit patients with C2 and C3 disease and
11 follow the progress of their disease over a number of years. Consideration
12 should be given to including a genetic component in the study because
13 genetic factors have not been studied on a large scale. The results of such a
14 study should help to more accurately identify which patients are at risk of
15 developing more serious disease so that interventions can be offered at an
16 early stage to those who will benefit most.

17 **2.2** ***Compression as a management option***

18 What is the clinical and cost effectiveness of compression hosiery versus no
19 compression for managing symptomatic varicose veins?

20 **Why this is important**

21 Compression hosiery is widely used as first-line treatment for symptomatic
22 varicose veins. In some areas of the UK, a period of hosiery use is a
23 precursor to referral to secondary care.

24 Discomfort and difficulty in application may cause people to stop wearing
25 compression hosiery or wear it only occasionally. The current evidence for the
26 benefit of compression hosiery is weak. There is little evidence of an impact
27 on symptom relief or an improvement in quality of life. It is therefore not
28 possible to calculate the cost effectiveness of compression hosiery.

29 A multicentre trial randomising compression hosiery versus no compression in
30 patients with symptomatic varicose veins is needed. The trial should evaluate

1 quality of life, including symptom reduction, and measure adherence with
2 compression hosiery. In addition, the trial should investigate the impact of
3 compression on disease progression and the need for subsequent
4 intervention.

5 **2.3 *Compression after interventional treatment***

6 What is the clinical and cost effectiveness of compression hosiery after
7 interventional treatment for varicose veins compared with no compression
8 hosiery? If there is benefit, how long should compression hosiery be worn for?

9 **Why this is important**

10 The benefit of compression after interventional treatment for varicose veins is
11 unclear. A well conducted multicentre randomised controlled trial (RCT) of
12 compression hosiery after each of the 3 main interventional treatments would
13 help determine whether compression hosiery is beneficial, and if so, what type
14 of compression is best and how long it should be worn for. There should be 6
15 RCT arms, 1 arm with compression and 1 arm without in each of 3 patient
16 groups:

- 17 • patients who have had endothermal ablation
- 18 • patients who have had ultrasound-guided foam sclerotherapy
- 19 • patients who have had surgery.

20 Each arm should have subgroups for compression type and duration.
21 Adherence to treatment with compression hosiery and the effect of adherence
22 on effectiveness should also be evaluated. A cost-effectiveness analysis
23 should be performed. If compression hosiery is beneficial, such a trial should
24 help improve quality of life for people with varicose veins and reduce the
25 longer-term need for retreatment.

26 **2.4 *Truncal treatment with or without concurrent*** 27 ***tributary treatment***

28 What is the clinical and cost effectiveness of concurrent phlebectomies for
29 varicose tributaries during truncal endothermal ablation for varicose veins
30 compared with:

- 1 • truncal endothermal ablation without concurrent phlebectomies
- 2 • truncal endothermal ablation with subsequent phlebectomies, if needed, 6–
- 3 12 weeks later.

4 **Why this is important**

5 Conventional truncal stripping under general anaesthetic involves
6 synchronous phlebectomies of varicose tributaries, and in ultrasound-guided
7 foam sclerotherapy truncal and tributary veins are treated concurrently. In
8 contrast, endothermal ablation may be performed alone to obliterate truncal
9 incompetence, or synchronously with phlebectomies, and current practice
10 varies.

11 Synchronous tributary treatment ensures a single treatment episode, and the
12 removal of all symptomatic varicosities leads to a better immediate quality of
13 life, but this takes longer and thus may be associated with increased
14 morbidity. Deferred tributary treatment may reduce morbidity, and also mean
15 that some patients do not need tributary treatment (or need fewer tributary
16 treatments on smaller veins). However, it involves 2 interventions for patients
17 who need tributary treatment. Omitting tributary treatments entirely ensures a
18 single treatment episode, but it is unclear whether remaining varicosities will
19 persist and impair quality of life.

20 At present, there is limited evidence from 1 small-scale (n=50) study on the
21 use and timing of tributary treatments after truncal endothermal ablation
22 treatment. There is a need for practice to be based on empirical evidence
23 from a large and sufficiently powered RCT comparing all 3 main intervention
24 options (no tributary treatment, concurrent tributary treatment and delayed
25 tributary treatment).

26 **2.5 *Interventional treatment for people with CEAP stage*** 27 ***C6 disease (leg ulcers) and varicose veins***

28 Does the early interventional treatment of superficial venous reflux together
29 with compression therapy improve wound healing and result in greater cost

1 effectiveness compared with compression therapy alone in patients with
2 chronic venous ulceration?

3 **Why this is important**

4 Chronic venous leg ulcers are a common major cause of morbidity. Quality of
5 life for patients with venous leg ulcers is substantially reduced by discomfort
6 and social isolation resulting from odour and wound discharge. The social and
7 personal impact of chronic venous leg ulceration is therefore considerable.

8 Only 1 study has been completed in which surgery and compression were
9 compared with compression alone. This showed improvement in the rates of
10 ulcer recurrence. It would now be suitable to consider endovenous
11 interventional techniques which, being a minimally invasive procedure, are
12 more acceptable to patients.

13 At present, ulceration is often managed with compression, despite poor
14 success rates. A high-quality, large-scale randomised trial evaluating
15 outcomes after early interventional treatment compared with compression
16 therapy is needed.

17 **3 Other information**

18 **3.1 *Scope and how this guideline was developed***

19 NICE guidelines are developed in accordance with a [scope](#) that defines what
20 the guideline will and will not cover.

How this guideline was developed

NICE commissioned the National Clinical Guideline Centre to develop this guideline. The Centre established a Guideline Development Group (see section 4), which reviewed the evidence and developed the recommendations.

The methods and processes for developing NICE clinical guidelines are described in [The guidelines manual](#).

21

1 **3.2 Related NICE guidance**

2 Details are correct at the time of consultation on the guideline (February
3 2013). Further information is available on [the NICE website](#).

4 **Published**

5 **General**

- 6 • [Patient experience in adult NHS services](#). NICE clinical guidance 138
7 (2012).

8 **Condition-specific**

- 9 • [Ultrasound-guided foam sclerotherapy for varicose veins](#). NICE
10 interventional procedure guidance 440 (2013).
- 11 • [Promoting physical activity in the workplace](#). NICE public health guidance
12 13 (2008).
- 13 • [Smoking cessation services](#). NICE public health guidance 10 (2008).
- 14 • [Physical activity and the environment](#). NICE public health guidance 8
15 (2008).
- 16 • [Obesity](#). NICE clinical guideline 43 (2006).
- 17 • [Four commonly used methods to increase physical activity](#). NICE public
18 health guidance 2 (2006).
- 19 • [Brief interventions and referral for smoking cessation](#). NICE public health
20 guidance 1 (2006).
- 21 • [Endovenous laser treatment of the long saphenous vein](#). NICE
22 interventional procedure guidance 52 (2004).
- 23 • [Transilluminated powered phlebectomy for varicose veins](#). NICE
24 interventional procedure guidance 37 (2004).
- 25 • [Radiofrequency ablation of varicose veins](#). NICE interventional procedure
26 guidance 8 (2003).

27

1 **4 The Guideline Development Group, National**
2 **Collaborating Centre and NICE project team**

3 **4.1 Guideline Development Group**

4 **Alun Davies (Chair)**

5 Professor of Vascular Surgery, Imperial College London and Honorary
6 Consultant Surgeon, Imperial College NHS Trust, Charing Cross and St
7 Mary's Hospitals, London

8 **Mustapha Azzam**

9 MD Vascular Scientist/Phlebologist, Ealing NHS Trust, Imperial College,
10 London

11 **Andrew Bradbury**

12 Sampson Gamgee Professor of Vascular Surgery and Director of Quality
13 Assurance and Enhancement, College of Medical and Dental Sciences,
14 University of Birmingham and Consultant Vascular and Endovascular
15 Surgeon, Heart of England NHS Foundation Trust, Birmingham

16 **Jocelyn Brookes**

17 Consultant Endovascular Radiologist, University College London Hospitals

18 **Joyce Calam**

19 Patient member

20 **David Evans**

21 Patient member

22 **Nick Hickey**

23 Consultant Vascular Surgeon, Worcestershire Acute Hospitals NHS Trust,
24 Worcester

25 **Keith Poskitt**

26 Consultant Vascular Surgeon, Cheltenham General Hospital, Gloucestershire
27 Hospitals NHS Foundation Trust

1 **Hazel Trender**
2 Vascular Nurse Specialist, Sheffield Vascular Institute

3 **Mark Vaughn**
4 GP, Llanelli, Carmarthenshire

5 **4.2 National Clinical Guideline Centre**

6 **Kate Kelley**
7 Guideline Lead

8 **Quyen Chu**
9 Senior Project Manager and Research Fellow

10 **Katharina Dworzynski**
11 Senior Research Fellow

12 **Karen Head**
13 Senior Project Manager and Research Fellow

14 **Grace Marsden**
15 Health Economist

16 **Mark Perry**
17 Research Fellow

18 **Ebenezer Tetteh**
19 Senior Health Economist

20 **Richard Whittome**
21 Information Scientist

22 **4.3 NICE project team**

23 **Sharon Summers-Ma**
24 Associate Director

25 **Caroline Keir**
26 Guideline Commissioning Manager

DRAFT FOR CONSULTATION

- 1 **Margaret Ghلامي**
- 2 Guideline Coordinator

- 3 **Steven Barnes**
- 4 Technical Lead

- 5 **Prashanth Kandaswamy**
- 6 Health Economist

- 7 **Judy McBride**
- 8 Editor

- 9